Home The Word Brain My Amedeo FAQ Privacy About Flying Publisher   


OLIENA
Language recovery after stroke
App | Video | PDF (278 pp) | Web

  Schizophrenia

  Free Subscription


18.02.2019

1 Br J Psychiatry
1 Clin Neuropharmacol
2 J Abnorm Psychol
1 J Clin Psychopharmacol
9 Mol Psychiatry
2 Neuropsychopharmacology
2 Psychol Med
9 Schizophr Res


  Retrieve available abstracts of this week’s articles:
HTML format
Text format
 
 
Single Articles


    Br J Psychiatry

  1. TOROUS J, Woodyatt J, Keshavan M, Tully LM, et al
    A new hope for early psychosis care: the evolving landscape of digital care tools.
    Br J Psychiatry. 2019 Feb 11:1-4. doi: 10.1192/bjp.2019.
    PubMed     Text format     Abstract available


    Clin Neuropharmacol

  2. SPIEGEL DR, Glad R, Smith M, Raja U, et al
    A Case of Schizophrenia With Catatonia Resistant to Lorazepam and Olanzapine Monotherapy But Responsive to Combination Treatment: Is It Time to Consider Using Select Second-Generation Antipsychotics Earlier in the Treatment Algorithm for This Patient
    Clin Neuropharmacol. 2019 Feb 12. doi: 10.1097/WNF.0000000000000327.
    PubMed     Text format     Abstract available


    J Abnorm Psychol

  3. AFE T, Adegbohun AA, Ogunsemi O, Osalusi B, et al
    Gender and obstetric factors in the determination of the age of onset of schizophrenia in a Nigerian cohort.
    J Abnorm Psychol. 2019 Feb 14. pii: 2019-07473-001. doi: 10.1037/abn0000386.
    PubMed     Text format     Abstract available

  4. SCHWARTZ EK, Docherty NM, Najolia GM, Cohen AS, et al
    Exploring the racial diagnostic bias of schizophrenia using behavioral and clinical-based measures.
    J Abnorm Psychol. 2019 Feb 14. pii: 2019-07478-001. doi: 10.1037/abn0000409.
    PubMed     Text format     Abstract available


    J Clin Psychopharmacol

  5. KUCUKGONCU S, Guloksuz S, Tek C
    Effects of Curcumin on Cognitive Functioning and Inflammatory State in Schizophrenia: A Double-Blind, Placebo-Controlled Pilot Trial.
    J Clin Psychopharmacol. 2019 Feb 8. doi: 10.1097/JCP.0000000000001012.
    PubMed     Text format    


    Mol Psychiatry

  6. XU J, Hartley BJ, Kurup P, Phillips A, et al
    Inhibition of STEP61 ameliorates deficits in mouse and hiPSC-based schizophrenia models.
    Mol Psychiatry. 2018;23:271-281.
    PubMed     Text format     Abstract available

  7. SCARR E, Udawela M, Thomas EA, Dean B, et al
    Changed gene expression in subjects with schizophrenia and low cortical muscarinic M1 receptors predicts disrupted upstream pathways interacting with that receptor.
    Mol Psychiatry. 2018;23:295-303.
    PubMed     Text format     Abstract available

  8. EHRENREICH H, Mitjans M, Van der Auwera S, Centeno TP, et al
    OTTO: a new strategy to extract mental disease-relevant combinations of GWAS hits from individuals.
    Mol Psychiatry. 2018;23:476-486.
    PubMed     Text format     Abstract available

  9. ST POURCAIN B, Robinson EB, Anttila V, Sullivan BB, et al
    ASD and schizophrenia show distinct developmental profiles in common genetic overlap with population-based social communication difficulties.
    Mol Psychiatry. 2018;23:263-270.
    PubMed     Text format     Abstract available

  10. NOTTER T, Coughlin JM, Gschwind T, Weber-Stadlbauer U, et al
    Translational evaluation of translocator protein as a marker of neuroinflammation in schizophrenia.
    Mol Psychiatry. 2018;23:323-334.
    PubMed     Text format     Abstract available

  11. ROFFMAN JL, Petruzzi LJ, Tanner AS, Brown HE, et al
    Biochemical, physiological and clinical effects of l-methylfolate in schizophrenia: a randomized controlled trial.
    Mol Psychiatry. 2018;23:316-322.
    PubMed     Text format     Abstract available

  12. PAGE SC, Hamersky GR, Gallo RA, Rannals MD, et al
    The schizophrenia- and autism-associated gene, transcription factor 4 regulates the columnar distribution of layer 2/3 prefrontal pyramidal neurons in an activity-dependent manner.
    Mol Psychiatry. 2018;23:304-315.
    PubMed     Text format     Abstract available

  13. ZILHAO NR, Abdellaoui A, Smit DJA, Cath DC, et al
    Polygenic prediction of obsessive compulsive symptoms.
    Mol Psychiatry. 2018;23:168-169.
    PubMed     Text format    

  14. COLIZZI M, Weltens N, McGuire P, Lythgoe D, et al
    Delta-9-tetrahydrocannabinol increases striatal glutamate levels in healthy individuals: implications for psychosis.
    Mol Psychiatry. 2019 Feb 15. pii: 10.1038/s41380-019-0374.
    PubMed     Text format     Abstract available


    Neuropsychopharmacology

  15. STJEPAN C, Gregor L, Stephanie T, Christina A, et al
    Reduced auditory evoked gamma-band response and schizophrenia-like clinical symptoms under subanesthetic ketamine.
    Neuropsychopharmacology. 2019 Feb 6. pii: 10.1038/s41386-019-0328.
    PubMed     Text format     Abstract available

  16. WYNN JK, Green MF, Hellemann G, Reavis EA, et al
    A dose-finding study of oxytocin using neurophysiological measures of social processing.
    Neuropsychopharmacology. 2019;44:289-294.
    PubMed     Text format     Abstract available


    Psychol Med

  17. PLAVEN-SIGRAY P, Cervenka S
    Meta-analytic studies of the glial cell marker TSPO in psychosis - a question of apples and pears?
    Psychol Med. 2019 Feb 11:1-5. doi: 10.1017/S003329171800421.
    PubMed     Text format    

  18. JAUHAR S, Laws KR, McKenna PJ
    CBT for schizophrenia: a critical viewpoint.
    Psychol Med. 2019 Feb 13:1-4. doi: 10.1017/S0033291718004166.
    PubMed     Text format    


    Schizophr Res

  19. JOSHI YB, Thomas ML, Hochberger WC, Bismark AW, et al
    Verbal learning deficits associated with increased anticholinergic burden are attenuated with targeted cognitive training in treatment refractory schizophrenia patients.
    Schizophr Res. 2019 Feb 6. pii: S0920-9964(19)30025.
    PubMed     Text format     Abstract available

  20. SOLLYCHIN M, Jack BN, Polari A, Ando A, et al
    Frontal slow wave resting EEG power is higher in individuals at Ultra High Risk for psychosis than in healthy controls but is not associated with negative symptoms or functioning.
    Schizophr Res. 2019 Feb 6. pii: S0920-9964(19)30042.
    PubMed     Text format     Abstract available

  21. CHUNG Y, Addington J, Bearden CE, Cadenhead K, et al
    Adding a neuroanatomical biomarker to an individualized risk calculator for psychosis: A proof-of-concept study.
    Schizophr Res. 2019 Feb 7. pii: S0920-9964(19)30023.
    PubMed     Text format     Abstract available

  22. MILLER BJ, Claxton A, Du Y, Weiden PJ, et al
    Switching patients with schizophrenia from paliperidone palmitate to aripiprazole lauroxil: A 6-month, prospective, open-label study.
    Schizophr Res. 2019 Feb 7. pii: S0920-9964(19)30041.
    PubMed     Text format     Abstract available

  23. LOPILATO AM, Goines K, Addington J, Bearden CE, et al
    Impact of childhood adversity on corticolimbic volumes in youth at clinical high-risk for psychosis.
    Schizophr Res. 2019 Feb 7. pii: S0920-9964(19)30050.
    PubMed     Text format     Abstract available

  24. WIJTENBURG SA, Kapogiannis D, Korenic SA, Mullins RJ, et al
    Brain insulin resistance and altered brain glucose are related to memory impairments in schizophrenia.
    Schizophr Res. 2019 Feb 11. pii: S0920-9964(19)30034.
    PubMed     Text format     Abstract available

  25. SHIMAMOTO-MITSUYAMA C, Ohnishi T, Balan S, Ohba H, et al
    Evaluation of the role of fatty acid-binding protein 7 in controlling schizophrenia-relevant phenotypes using newly established knockout mice.
    Schizophr Res. 2019 Feb 11. pii: S0920-9964(19)30052.
    PubMed     Text format     Abstract available

  26. MONDELLI V, Dazzan P
    Childhood trauma and psychosis: Moving the field forward.
    Schizophr Res. 2019 Feb 11. pii: S0920-9964(19)30051.
    PubMed     Text format    

  27. DYKXHOORN J, Hollander AC, Lewis G, Dalman C, et al
    Family networks during migration and risk of non-affective psychosis: A population-based cohort study.
    Schizophr Res. 2019 Feb 7. pii: S0920-9964(19)30047.
    PubMed     Text format     Abstract available


Thank you for your interest in scientific medicine.


AMEDEO Schizophrenia is free of charge.
This policy is made possible thanks to a media sponsorship by Boehringer Ingelheim.

Design: